A
Allogene Therapeutics, Inc. (ALLO)
NMS – Real vaqt narxi. Valyuta: USD
2.13
+0.07 (3.40%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.13
-0.00 (-0.01%)
Bozordan keyin: Jun 26, 2026, 7:54 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
2.13
+0.07 (3.40%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.13
-0.00 (-0.01%)
Bozordan keyin: Jun 26, 2026, 7:54 PM EDT
Allogene Therapeutics, Inc. – bu saraton va autoimmun kasalliklarni davolash uchun genetik jihatdan muhandislik qilingan allogen T-hujayrali terapiyalarni ishlab chiqish va tijoratlashtiruvchi klinik bosqichdagi immuno-onkologiya kompaniyasi. U oqsil muhandisligi, gen tahrirlash, gen qo'shish va ilg'or patentlangan T-hujayra ishlab chiqarish texnologiyalaridan foydalangan holda, bir nechta allogen CAR T-hujayrali mahsulot nomzodlaridan iborat bir qatorni ishlab chiqadi. Kompaniya, shuningdek, katta B-hujayrali limfomani (LBCL) davolash uchun CD19ni nishonga oladigan muhandislik qilingan allogen CAR T-hujayrali mahsulot nomzodi bo'lgan cemacabtagene ansegedleucel (cema-cel)ni ishlab chiqmoqda. Bundan tashqari, u buyrak hujayrali karsinomani (RCC) davolash uchun CD70ni nishonga oladigan muhandislik qilingan allogen CAR T-hujayrali mahsulot nomzodi bo'lgan ALLO-316ni; va tizimli lupus eritematoz (SLE), idiopatik yallig'lanishli miyopatiyalar (IIM) va tizimli skleroz (SSc) kabi autoimmun kasalliklarni (AID) davolash uchun CD19 va CD70 ikkalasini ham nishonga oladigan muhandislik qilingan allogen CAR T-hujayrali mahsulot nomzodi bo'lgan ALLO-329ni ishlab chiqmoqda. Kompaniya 2017 yilda ro'yxatga olingan va uning shtab-kvartirasi Janubiy San-Fransisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Zachary J. Roberts M.D., Ph.D. | Executive VP of Research & Development and Chief Medical Officer |
| Mr. Benjamin M. Beneski | Senior VP & Chief Technical Officer |
| Mr. Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary |
| Mr. Geoffrey M. Parker | Executive VP & CFO |
| Mr. Joshua A. Kazam | Co-Founder & Director |
| Ms. Annie Yoshiyama | SVP & Corporate Controller |
| Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer |
| Ms. Susan R. Lundeen | Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-28 | DEFA14A | d345357ddefa14a.htm |
| 2026-05-28 | 8-K | d65280d8k.htm |
| 2026-05-21 | DEFA14A | allo-20260520xdefa14a.htm |
| 2026-05-13 | 8-K | allo-20260512.htm |
| 2026-05-13 | 10-Q | allo-20260331.htm |
| 2026-04-30 | DEF 14A | allo-20260430.htm |
| 2026-04-20 | PRE 14A | allo-20260420.htm |
| 2026-04-15 | 8-K | d283634d8k.htm |
| 2026-04-13 | 8-K | d49895d8k.htm |
| 2026-03-12 | S-8 | allogene-formsx8x20260312.htm |